[{"id":"652d5ab0-cd46-459c-90cb-214f85150b09","acronym":"","url":"https://clinicaltrials.gov/study/NCT02688881","created_at":"2021-01-18T13:06:49.957Z","updated_at":"2024-07-02T16:36:08.876Z","phase":"Phase 4","brief_title":"Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors","source_id_and_acronym":"NCT02688881","lead_sponsor":"Samsung Medical Center","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation • PIK3CA H1047R • PIK3CA E545K • PIK3CA amplification • PIK3CA E542K • PIK3CA E545 • PIK3CA E542 • AKT1 amplification","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PIK3CA H1047R • PIK3CA E545K • PIK3CA amplification • PIK3CA E542K • PIK3CA E545 • PIK3CA E542 • AKT1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 02/05/2017","start_date":" 02/05/2017","primary_txt":" Primary completion: 12/30/2020","primary_completion_date":" 12/30/2020","study_txt":" Completion: 02/24/2021","study_completion_date":" 02/24/2021","last_update_posted":"2022-06-15"},{"id":"fac4bd62-7009-4c63-9d58-007fc498b1b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02451956","created_at":"2021-01-18T11:45:26.832Z","updated_at":"2024-07-02T16:36:52.012Z","phase":"Phase 2","brief_title":"Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy","source_id_and_acronym":"NCT02451956","lead_sponsor":"Samsung Medical Center","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation • PIK3CA amplification","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PIK3CA amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Truqap (capivasertib)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 01/07/2015","start_date":" 01/07/2015","primary_txt":" Primary completion: 05/24/2019","primary_completion_date":" 05/24/2019","study_txt":" Completion: 05/24/2019","study_completion_date":" 05/24/2019","last_update_posted":"2019-12-30"},{"id":"5b4fe831-7154-449c-a7e0-1ea194af8830","acronym":"","url":"https://clinicaltrials.gov/study/NCT02449564","created_at":"2021-01-18T11:44:39.206Z","updated_at":"2024-07-02T16:37:14.783Z","phase":"","brief_title":"The Pilot Study Evaluate the Safety and Efficacy of Sirolimus in Patients With PIK3CA Mutation and/or PIK3CA Amplification Refractory Solid Tumors","source_id_and_acronym":"NCT02449564","lead_sponsor":"Samsung Medical Center","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation • PIK3CA amplification","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PIK3CA amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 11/24/2014","start_date":" 11/24/2014","primary_txt":" Primary completion: 09/27/2017","primary_completion_date":" 09/27/2017","study_txt":" Completion: 11/03/2017","study_completion_date":" 11/03/2017","last_update_posted":"2018-01-17"},{"id":"86016884-d6ee-490d-bf5d-5bac693c02a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01493843","created_at":"2021-01-18T06:15:28.162Z","updated_at":"2024-07-02T16:37:23.101Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01493843","lead_sponsor":"Genentech, Inc.","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA amplification • PTEN-L","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA amplification • PTEN-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • paclitaxel • pictilisib (GDC-0941)"],"overall_status":"Completed","enrollment":" Enrollment 501","initiation":"Initiation: 01/20/2012","start_date":" 01/20/2012","primary_txt":" Primary completion: 03/30/2016","primary_completion_date":" 03/30/2016","study_txt":" Completion: 03/30/2016","study_completion_date":" 03/30/2016","last_update_posted":"2017-04-25"},{"id":"f31ddc5c-cd83-45d1-a84d-30869a51da44","acronym":"","url":"https://clinicaltrials.gov/study/NCT02449538","created_at":"2021-01-18T11:44:37.973Z","updated_at":"2024-07-02T16:37:25.609Z","phase":"Phase 2","brief_title":"Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors","source_id_and_acronym":"NCT02449538","lead_sponsor":"Samsung Medical Center","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation • PIK3CA amplification","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PIK3CA amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 08/01/2016","study_completion_date":" 08/01/2016","last_update_posted":"2017-02-17"}]